| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Common dietary herbal flavonoid asstilbin can be found in a wide range of foods, including red wine, astragalus, sarsaparilla, and grapes. Cell growth produced by platinum was considerably suppressed and recovered by astelbin. Astilbin first stops the cisplatin-induced preservation of HEK-293 cells before dramatically reducing the buildup of reactive oxygen species (ROS) and attenuating ROS-induced activation of p53, MAPK, and AKT signaling cascades. In HEK-293 cells produced by cisplatin induction, astelbin efficiently reduces the formation of ROS by enhancing NRF2 activation and inhibiting the termination of antioxidant genes. Astilbin strongly suppresses the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), as well as the activation of NF-κB and tumor factor α (TNF-α). HEK-293 cells were treated with either 200 μM of Astilbin or 100 μM of CDDP to see how these treatments affected the proliferation of the kidney cells treated with CDDP. HEK-293 cells treated with astelbin showed a considerable improvement in CDDP-induced cell proliferation [1].
|
|---|---|
| ln Vivo |
In order to investigate whether astelbin mitigates CDDP-induced nephrotoxicity in vivo, a mouse model of fast cisplatin nephrotoxicity was created. Much less weight was gained after receiving a single 8 mg/kg injection of CDDP than before the vacation. At a dose of 50 mg/kg, astelbin caused a much larger occurrence of this event. No discernible changes in body weight were observed in mice fed Astilbin alone. Mice treated with CDDP also had similar blood urea nitrogen (BUN) and serum myochrome (SCr) profiles. To conduct simulations, Astilbin was used. Both SCr and BUN were lowered throughout treatment. Astilbin's preventive efficacy against renal histopathological damage caused by CDDP was investigated using H&E staining. When compared to the CDDP group model, which showed severe kidney damage including renal tubular degeneration, bone marrow, renal tubule cystic dilatation, and proximity to focal heart disease, the kidney damage morphology of the dye and astelbin treated groups was normal. In comparison to the CDDP group, astelbin reduced renal damage and corresponding pathology scores. Astilbin therapy may be able to lessen CDDP-induced acute nephrotoxicity in mice receiving renal cell transplantation, as determined by TUNEL staining [1].
|
| References | |
| Additional Infomation |
Astilbin is a flavanone glycoside that is (+)-taxifolin substituted by a alpha-L-rhamnosyl moiety at position 3 via a glycosidic linkage. It has a role as a radical scavenger, an anti-inflammatory agent and a plant metabolite. It is an alpha-L-rhamnoside, a member of 3'-hydroxyflavanones, a tetrahydroxyflavanone, a flavanone glycoside, a monosaccharide derivative and a member of 4'-hydroxyflavanones. It is functionally related to a (+)-taxifolin. It is an enantiomer of a neoastilbin.
Astilbin has been reported in Neolitsea aurata, Hymenaea martiana, and other organisms with data available. Astilbin is a metabolite found in or produced by Saccharomyces cerevisiae. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.3928
|
| Exact Mass |
450.116
|
| CAS # |
29838-67-3
|
| PubChem CID |
119258
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
801.1±65.0 °C at 760 mmHg
|
| Melting Point |
179 - 180 °C
|
| Flash Point |
282.9±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O
|
| InChi Key |
ZROGCCBNZBKLEL-MPRHSVQHSA-N
|
| InChi Code |
InChI=1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3/t7-,15-,17+,18+,19+,20-,21-/m0/s1
|
| Chemical Name |
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~222.03 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
